Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Soft Tissue Sarcoma Market Size

ID: MRFR//3862-HCR | 90 Pages | Author: Rahul Gotadki| April 2024

Soft tissue sarcoma (STS) represents a diverse group of rare cancers that originate in the soft tissues of the body, including muscles, fat, nerves, and blood vessels. The market for soft tissue sarcoma has undergone notable developments in recent years, with advancements in research, diagnosis, and treatment options. Soft tissue sarcoma can manifest in various locations and exhibit diverse histological subtypes, making it a complex challenge for both clinicians and researchers.

In the realm of soft tissue sarcoma, early detection and accurate diagnosis are critical factors influencing patient outcomes. As technology has progressed, there has been a concerted effort to enhance diagnostic methods, including imaging techniques and molecular pathology. These improvements contribute to more precise identification and classification of soft tissue sarcomas, aiding in personalized treatment approaches.

The treatment landscape for soft tissue sarcoma has witnessed significant evolution, with a shift towards multidisciplinary approaches. Surgery remains a cornerstone in the management of localized tumors, often complemented by radiation therapy. However, for advanced or metastatic cases, systemic therapies such as chemotherapy and targeted therapies have gained prominence. Researchers and pharmaceutical companies are actively engaged in developing novel agents and therapeutic strategies to address the unmet needs in this challenging disease.

Clinical trials play a pivotal role in advancing soft tissue sarcoma research and expanding treatment options. These trials evaluate the safety and efficacy of innovative therapies, ranging from immunotherapies to targeted drugs. The involvement of patients in clinical trials not only provides them access to cutting-edge treatments but also contributes valuable data to the scientific community, fostering progress in the field.

Market dynamics in soft tissue sarcoma are influenced by factors such as the rarity of the disease, regulatory pathways, and the competitive landscape among pharmaceutical companies. The orphan drug designation and fast-track approvals granted by regulatory authorities have incentivized research and development efforts in this niche area. Additionally, collaborations between academia, industry, and advocacy groups play a pivotal role in driving research forward and ensuring a holistic approach to addressing the challenges posed by soft tissue sarcoma.

Patient advocacy and awareness initiatives have gained momentum, shedding light on the unique needs of individuals affected by soft tissue sarcoma. The patient community plays an active role in shaping research priorities, advocating for increased funding, and fostering a supportive environment for those grappling with the disease. As awareness grows, there is a heightened focus on improving the quality of life for soft tissue sarcoma patients through comprehensive care and psychosocial support.

Despite the progress made, soft tissue sarcoma remains a formidable health challenge, necessitating ongoing collaboration and innovation. The market for soft tissue sarcoma is poised for further growth, driven by advancements in diagnostic technologies, the expansion of targeted therapies, and the exploration of immunotherapeutic interventions. The evolving landscape offers hope for improved outcomes and an enhanced quality of life for individuals facing the complexities of soft tissue sarcoma. As research and development efforts continue, the collaborative spirit of the scientific and patient communities will undoubtedly play a crucial role in shaping the future trajectory of the soft tissue sarcoma market.

Global Soft Tissue Sarcoma Market Overview


Soft Tissue Sarcoma Market Size was valued at USD 1.15 billion in 2022 and is projected to grow from USD 1.27 Billion in 2023 to USD 2.37 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.9% during the forecast period (2023 - 2032). Factors such as new product launches, increased use of newer therapies, and a larger target population are the key market drivers enhancing market growth.Soft Tissue Sarcoma MarketSource: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Key market drivers boosting market growth include the introduction of new products, the widespread use of innovative medicines, and an expansion of the target audience. A major factor propelling the soft tissue sarcoma market is the discovery and development of novel therapeutics. Over the past decade, there has been an explosion in the availability of innovative drugs and therapies for the treatment of soft tissue sarcoma. Patients and doctors alike benefit from the expanded treatment options and enhanced effectiveness made possible by these ground-breaking pharmaceuticals.


Surgery followed by radiation or chemotherapy as neoadjuvant or adjuvant therapy has been the standard treatment for localized sarcomas for over 40 years. However, around 50% of individuals with moderate or high grade sarcoma still develop metastatic illness, even after complete surgical resection. The paradigm for treating sarcoma has shifted significantly with the development of targeted therapy. Growth of the market is expected to be substantially influenced by targeted therapeutics and pipeline advancements throughout the projected period.


There is a significant opening for the development of innovative first-in-class medicines due to the prevalence of unmet demands in the market. Seven of the 45 sarcoma medications in development are at the Phase III stage, 22 are at the Phase II stage, two are in combined Phase I/II trials, and the remaining treatments are in either Phase I or Pre-clinical testing. Phase I/II clinical trials are now assessing the potential use of immuno-oncology medicines in the treatment of sarcomas. As a result, the expansion of the market is facilitated by these efforts.


In 2020, the majority of the reported deals will have been founded within the last three years. The majority of the deals involved licenses (55%). In addition, more than half of the contracts were for liposarcoma treatments. Together, all these alliances open up numerous prospects for the expansion of the sector.


in August 2023, the Pharmaceutical Benefits Scheme (PBS) will begin providing new treatments for chronic migraine and soft tissue sarcoma to Australians. Eptinezumab (Vyepti) will now be available on the PBS, making it more affordable for people with chronic migraine who haven't reacted to or are intolerant to existing preventive drugs. It is estimated that more than 4,500 individuals will benefit from Vyepti, the first intravenous calcitonin gene related peptide (CGRP) inhibitor medication for migraine prevention to be included on the PBS.


 


Soft Tissue Sarcoma Market Trends



  • Development of new and innovative therapies to boost the market growth


The development of new and innovative medicines is a key driver in the soft tissue sarcoma market. There has been a dramatic increase in the number of novel medications and therapies licensed for the treatment of soft tissue sarcoma over the previous decade. For example, the FDA approved trabectedin (Yondelis), a chemotherapeutic medication, in 2015 for the treatment of liposarcoma and leiomyosarcoma, two kinds of soft tissue sarcoma. Pazopanib (Votrient), for example, was licensed by the FDA in 2012 for the treatment of advanced soft tissue sarcoma.


These innovative medicines provide additional treatment options and improved outcomes for patients and healthcare providers. Pazopanib, for example, was found to improve progression-free survival in patients with advanced soft tissue sarcoma by a median of 3 months when compared to a placebo in a phase 3 clinical trial. Similarly, trabectedin has increased progression-free survival in liposarcoma and leiomyosarcoma patients. These factors are projected to fuel Soft Tissue Sarcoma market revenue expansion in the next years and improve market CAGR globally in recent years.


Soft Tissue Sarcoma Market Segment Insights


Soft Tissue Sarcoma Treatment Insights


The global Soft Tissue Sarcoma market segmentation, based on treatment, includes Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, and Radiation Therapy. In 2022, the chemotherapy segment had the most market share in the soft tissue sarcoma market. Chemotherapy is a traditional treatment for soft tissue sarcoma, and numerous medicines, including doxorubicin, ifosfamide, and dacarbazine, are routinely utilized.


Targeted therapy, on the other hand, is an important and increasing part of the soft tissue sarcoma market. Targeted therapies, which are meant to attack specific chemicals or processes involved in the formation and growth of cancer cells, can provide considerable advantages over standard chemotherapy.


Soft Tissue Sarcoma Disease Type Insights


The global Soft Tissue Sarcoma market segmentation, based on Disease Type, includes Local Sarcoma, Regional Sarcoma, and Metastatic Sarcoma. In 2022, the local sarcoma segment dominated the soft tissue sarcoma market. Local sarcomas are tumors that are restricted to the place of origin and have not spread to neighboring lymph nodes or distant organs. Regional or metastatic sarcomas are often larger and more difficult to cure. Hence, the local sarcoma segment impacts the market growth.


FIGURE 2: SOFT TISSUE SARCOMA MARKET, BY DISEASE TYPES, 2022 & 2030 (USD BILLION)SOFT TISSUE SARCOMA MARKET, BY DISEASE TYPES, 2022 & 2030Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


June 2023: CancerVAX, Inc., maker of a revolutionary universal cancer vaccine that use the immune system to combat the disease, has announced the commencement of a $10 million financing round. The Company plans to use the funds raised from the SEC-approved Reg A+ sale to advance its ground-breaking cancer treatments. They are collaborating with UCLA to create targeted therapies for Ewing sarcoma, a particularly aggressive form of cancer that affects the bones and soft tissues of young people.


Soft Tissue Sarcoma Regional Insights


By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominated the soft tissue sarcoma market in 2022, followed by Europe and the Asia-Pacific region. This is attributable to the high prevalence of soft tissue sarcoma in North America and Europe, as well as the presence of modern healthcare infrastructure and R&D activity in these regions.


Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: SOFT TISSUE SARCOMA MARKET SHARE BY REGION 2022 (%)SOFT TISSUE SARCOMA MARKET SHARE BY REGION 2022Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


The European Soft Tissue Sarcoma market is the second largest shareholder in the global market. The European Medicines Agency (EMA) awarded conditional marketing authorization for Tazverik (tazemetostat) in the treatment of epithelioid sarcoma in adults in December 2021. Its approval follows the positive findings of tazemetostat's phase 2 clinical trial, which demonstrated significant tumor shrinking in patients with epithelioid sarcoma. Further, the Germany Soft Tissue Sarcoma market held the largest market share, and the UK Soft Tissue Sarcoma market was the fastest-growing market in the European region


Furthermore, the markets in Asia Pacific Soft Tissue Sarcoma market are expected to grow at the fastest compound annual growth rate (CAGR) over the forecast period. The China National Medical Products Administration (NMPA) approved Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST), a form of soft tissue sarcoma, in September 2021. Ayvakit is a tyrosine kinase inhibitor that specifically targets a genetic mutation found in some kinds of GIST. Moreover, China Soft Tissue Sarcoma market held the largest market share, and the India Soft Tissue Sarcoma market was the fastest-growing market in the Asia-Pacific region.


Soft Tissue Sarcoma Key Market Players & Competitive Insights


The soft tissue sarcoma market is highly competitive, with several major market players operating in the market. Market participants are also pursuing a variety of market developments to expand their global footprint, including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other companies. Competitors in the Soft Tissue Sarcoma industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


The Soft Tissue Sarcoma market major player such as GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services Inc. (U.S.), and Others.


GlaxoSmithKline plc (GSK) is a multinational pharmaceutical business based in the United Kingdom that develops and manufactures a wide range of prescription medications, vaccines, and consumer healthcare products. The corporation operates in over 150 countries and employs around 95,000 employees globally. GSK's oncology research focuses on discovering novel treatments for a variety of cancers, including soft tissue sarcoma. In this area, the company's research and development efforts are focused on identifying novel targets and creating tailored medicines to address the unique genetic alterations associated with different subtypes of soft tissue sarcoma.


Eli Lilly and Company is a multinational pharmaceutical corporation located in Indianapolis, Indiana, United States. Since its inception in 1876, the company has grown to become one of the world's major pharmaceutical corporations, with operations in over 120 countries and nearly 40,000 workers. Eli Lilly and Company is dedicated to finding breakthrough treatments for a wide range of malignancies, including soft tissue sarcoma, in the field of oncology. In this area, the company's research and development efforts are focused on identifying novel targets and creating tailored medicines to address the unique genetic alterations associated with different subtypes of soft tissue sarcoma.


Key Companies in the Soft Tissue Sarcoma market includes



  • GlaxoSmithKline plc (U.K)

  • Eli Lilly and Company (U.S.)

  • Pfizer Inc. (U.S.)

  • Bristol-Myers Squibb (U.S.)

  • Switzerland) Inc. (U.S.)

  • Johnson & Johnson Services Inc. (U.S.)

  • Others


Soft Tissue Sarcoma Industry Developments


Jan 2021: Pfizer stated that the European Commission had approved Vitrakvi (larotrectinib) for the treatment of advanced soft tissue sarcoma. Vitrakvi is a targeted therapy for individuals whose malignancies contain a specific genetic mutation.


 June 2021: Johnson & Johnson announced that its medicine JNJ-4528 had been approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. JNJ-4528, while not specific to soft tissue sarcoma, is a CAR-T cell therapy being developed for use in the treatment of a variety of malignancies, including some kinds of sarcoma.


Soft Tissue Sarcoma Market Segmentation


Soft Tissue Sarcoma Treatment Outlook



  • Targeted Therapy

  • Chemotherapy

  • Anti-Angiogenesis Drugs

  • Radiation Therapy


Soft Tissue Sarcoma Disease Type Outlook



  • Local Sarcoma

  • Regional Sarcoma

  • Metastatic Sarcoma


Soft Tissue Sarcoma Regional Outlook




  • North America



    • US

    • Canada




  • Europe



    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific



    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific




  • Rest of the World




    • Middle East




    • Africa




    • Latin America





Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.